Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2.

Uddman, Rolf; Tajti, J; Hou, M; Sundler, Frank; Edvinsson, Lars

Published in: Cephalalgia

DOI: 10.1046/j.1468-2982.2002.00324.x

2002

Link to publication


General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2

R Uddman, J Tajti, M Hou, F Sundler & L Edvinsson

1Department of Otorhinolaryngology, Malmö University Hospital, Malmö, Sweden, 2Department of Neurology, Albert Szent-Györgyi University Medical School, Szeged, Hungary, 3Department of Internal Medicine, Lund University Hospital, Lund, Sweden, and 4Department of Physiology and Neuroscience, Neuroendocrine Cell Biology, Lund University Hospital, Lund, Sweden

In migraine and other primary headaches there is a strong vascular component. Besides the trigeminovascular components some of the associated symptoms point to the involvement of brain stem regions. The central limb of the trigeminal vascular pathway is its projection to the trigeminal nucleus caudalis (TNC) and to the C1–C2 levels of the spinal cord. The aim of the present study was to demonstrate the occurrence of some neurotransmitters in these regions in man. In both the TNC and in the Rexed’s laminae I and II of the dorsal horns at the C1 and C2 levels there were numerous substance P immunoreactive fibres. Fibres containing calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide (PACAP) were moderately dense in number. Fibres containing vasoactive intestinal peptide (VIP) or nitric oxide synthase (NOS) were not seen in the TNC or at the C1 and C2 levels of the spinal cord.

Introduction

Much of the associated symptoms in attacks of primary headaches, e.g. pain, nausea and vomiting, suggest the involvement of brain stem regions. With positron emission tomography, Weiller et al. (1) demonstrated a centre in the brain stem that was activated in migraine attacks, thus linking the intracranial pain-sensitive blood vessels with central aspects of the migraine attack in man.

Studies in laboratory animals and in humans have revealed that the afferent innervation of the large intracranial blood vessels and the dura mater is primarily nociceptive and originates in the trigeminal ganglion (2–4). The bipolar trigeminal cells project centrally to the trigeminal nucleus caudalis (TNC) and its reciprocal parts at the C1 and C2 levels of the spinal cord. Recently, it has been observed that stimulation of the trigeminal ganglion results in the accumulation of the immediate early genes c-fos and c-jun in the Rexed’s laminae I and II of the TNC (5, 6). Stimulation of the superior sagittal sinus, used as a model for excitation of craniovascular pain, mimics several of the changes seen during a migraine attack in man (7, 8). Activation of the superior sagittal sinus by electrical or mechanical means increases the metabolic activity in the TNC and in the dorsal horns of the cervical spinal cord (8). In order to study which neurotransmitters might be involved in mediating the signalling in the central projections of the trigeminal nerve we have examined the occurrence of neurotransmitters previously shown to be expressed in the human trigeminal ganglion (9) in the human TNC and C1 and C2 regions.

Methods

Materials

Brain stem and cervical spinal cord were obtained at autopsy from adult subjects in accordance with the Hungarian University Medical School Guidelines for Ethics in Human Tissue Experiments. At autopsy the tissues were removed from six subjects (four male, two female) with an average age of 58.5 years (31–77 years).
None of the subjects suffered from any central nervous system diseases. Tissues were collected within 18–24 h of death.

**Fixation**

The brain stem was cut into 0.5 cm parts beginning at the level of the obex and ending below the spinal segment of C3. For immunocytochemistry, the tissues were immersed overnight in a fixative consisting of 2% paraformaldehyde and 0.2% picric acid in 0.1 mol/L phosphate buffer, pH 7.2. After fixation the tissues were rinsed and stored in Tyrode solution with 10% sucrose for 4 days.

**Freezing**

The tissue was put in a test tube filled with 50 ml of isopentane that had been stored in dry ice in a −85°C freezer for 20 min. After 10 s the tissue was removed and stored at −85°C until it was cut into 10-μm sections in a cryostat and mounted on chrome-alum coated slides.

**Immunocytochemistry**

For immunocytochemical demonstration of neuropeptides and neuronal NOSindirect immunofluorescence was used. For details of the antibodies see Table 1.

Briefly, the sections were incubated with the primary antibody overnight at +4°C. The site of the antigen–antibody complex was revealed by application of a secondary antibody (1 : 80; swine antirabbit IgG, DAKO, Copenhagen, Denmark) and conjugated to fluorescein isothiocyanate (FITC). In the control experiments the primary antibody was omitted.

The antibodies used were tested for specificity by preincubation with the respective antigen of related peptides (10–100 μg/ml diluted antibody).

Every twelfth section was stained with haematoxylin-eosin for neuroanatomical localization.

**Table 1** Details of antibodies used

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Dilution used</th>
<th>Made in</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>CGRP</td>
<td>1/2000</td>
<td>Rabbit</td>
<td>Euro-Diagnostica AB B 64–1</td>
</tr>
<tr>
<td>PACAP-38</td>
<td>1/800</td>
<td>Rabbit</td>
<td>Euro-Diagnostica AB B 57–1</td>
</tr>
<tr>
<td>SP</td>
<td>1/800</td>
<td>Rabbit</td>
<td>Euro-Diagnostica AB B 45–1</td>
</tr>
<tr>
<td>VIP</td>
<td>1/3000</td>
<td>Rabbit</td>
<td>Euro-Diagnostica AB B 34–1</td>
</tr>
<tr>
<td>NOS</td>
<td>1/1000</td>
<td>Rabbit</td>
<td>Euro-Diagnostica AB B 220–1</td>
</tr>
</tbody>
</table>

**Results**

**SP immunoreactivity**

The results are summarized in Table 2. There was a rich supply of substance P (SP) positive nerve fibres in the TNC that were located in the marginal layer and substantia gelatinosa of the subnucleus caudalis (Fig. 1). At the C1 and C2 levels a rich supply of SP-ir nerve fibres was also seen in Rexed’s laminae I and II and in the tract of Lissauer (Fig. 2).

**CGRP immunoreactivity**

The marginal layer and the substantia gelatinosa in the subnucleus caudalis of the TNC contained a moderate supply of calcitonin gene-related peptide (CGRP)-ir fibres (Fig. 1). CGRP positive cells were not observed. At the C1 and C2 levels, Rexed’s laminae I and II contained numerous CGRP-ir nerve fibres but no cell bodies, the inner layer being more heavily stained (Fig. 2). Also the tract of Lissauer had numerous CGRP-positive fibres at the C2 level.

**Table 2** Schematic representation of staining in the various regions with the different antibodies studied

<table>
<thead>
<tr>
<th>Antibody</th>
<th>TNC</th>
<th>C1</th>
<th>C2</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>PACAP</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CGRP</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>VIP</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>NOS</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Negative control</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>

Arbitrary scale: – no staining, + faint, ++ moderate, +++ rich staining.

A moderate amount of pituitary adenylate cyclase activating peptide (PACAP) positive fibres were found in the TNC, located in the marginal layer and substantia gelatinosa of the subnucleus caudalis of the TNC (Fig. 1).

A scarce to moderate amount of PACAP-ir fibres was observed at the C1 and C2 levels in the Rexed’s laminae I and II and in the tract of Lissauer (Fig. 2).

**VIP and NOS immunoreactivity**

Nerve fibres or cell bodies containing vasoactive intestinal peptide (VIP) or nitric oxide synthase (NOS) were...
neurotransmitters, such as SP, CGRP, PACAP, and NO (9). Electrical stimulation of the trigeminal ganglion in man and cat results in increased plasma levels of SP and CGRP in the jugular vein (16, 17).

The central structures that process craniovascular pain have to some degree been mapped. Stimulation of the trigeminal ganglion in the rat induces a reduction in the immunoreactivities of SP and CGRP in the TNC, ipsilateral to the stimulated side (18, 19). Electrical stimulation of the superior sagittal sinus in the cat leads to increased metabolic activity in the TNC and in the C2 region of the spinal cord (20). A marked increase of the immediate early gene c-fos in laminae I and II of the TNC and in the superficial layers of the C1 and C2 regions can be seen upon stimulation of the middle meningeal artery, the superior sagittal sinus or the trigeminal ganglion in monkeys and cats (21–23). This response is reduced by anti-migraine drugs, such as triptans (24–27).

In man, evidence for a central site of action of the triptans has come from binding studies that demonstrate, both in vitro and in vivo, their association with the superficial laminae of the caudal part of the TNC and the dorsal spinal cord, as well as of the nucleus of the tractus solitarius. In an attempt to characterize the receptors involved it has been suggested that the 5-HT1B receptors are present in very low concentrations in all these nuclei in man (below 12% of total specific binding), while the 5-HT1D receptors account for about 50% of the total specific sumatriptan binding (28). In addition, a significant number of 5-HT1F-binding sites can be seen (29, 30). The 5-HT1F site has been examined using a specific agonist LY334370 (31). LY334370 had no contractile effect and did not inhibit CGRP release. However, it was observed that LY334370 could block the transmission of nociceptive impulses in the TNC. These data gave weight to the proposal that the anti-migraine actions could in part be exerted centrally on these nuclei.

The present study in man has revealed that immunocytochemical distribution of SP-, CGRP- and PACAP-ir fibres coincides with the reported localization of the 5-HT1B/1D binding sites in the TNC and in particular with the distribution of 5-HT1B/1D receptor-ir. Thus, it is tempting to suggest that if the triptans can reach the TNC and the C1 and C2 levels, they may also here inhibit the activity of the central aspects of the sensory trigeminal fibres. It also suggests that the role of nitric oxide and VIP at this site is minor, although it cannot be ruled out that the effects of the post-mortem delay in combination with a long immersion period in the fixative may reduce the antigenicity of the NOS antibodies (32).

Acknowledgements

Supported by grants from the Swedish Medical Research Council (no 5958).

References


